Post A Reply

Rate Inspire Medical Systems

  • Culture

  • Compensation

  • Opportunity for advancement

  • Realistic plan attainment

×

Salaries

In our drive to help people in the medical sales industry we are gathering salary data. This information will be collated, analyzed and number crunched. Medtechy’s overall goal is to help the medical sales industry make more informed decisions when changing jobs and also keep employers and recruiters honest

Take 30 seconds and let us know your current deal.*

About The Position

Compensation

* We guarantee all data collected is completely anonymous and will only be used for the benefit of future visitors.

×

Hot Ticker Articles

Diversified growth lifts Boston Scientific in Q1

Mazor Robotics Q1 2018 Investor Presentation

Intuitive Surgical hits 2018 priorities. Blows past Q1 expectations

Johnson & Johnson medical device business delivers 7.5% growth in Q1

Boston Scientific marketing gets innovative with new video series

Job Listings

More big news - smaller, thinner, longer lasting device and new publications

Sleep Tech Will Widen the Gap Between the Rich and the Poor - Sleep Review

Some experts believe that sleep reduction gadgets will intensify the planet’s income inequality problem, reports Motherboard.

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

Now they're going public. Don't they still have coding issues?

YES

post

Now they're going public. Don't they still have coding issues?

Take a look at the Form S-1 filing...Sad state of affairs.

We have incurred net losses since our inception in 2007. For the years ended December 31, 2015, 2016 and 2017, we had net losses of $21.3 million, $18.5 million and $17.5 million, respectively. As of December 31, 2017, we had an accumulated deficit of $125.1 million. To date, we have financed our operations primarily through private placements of our convertible preferred stock, from sales of our Inspire system and amounts borrowed under our credit facility. We have devoted substantially all of our resources to research and development activities related to our Inspire system, including clinical and regulatory initiatives to obtain marketing approval, and sales and marketing activities.

Our pro forma net tangible book value as of December 31, 2017 was $1.5 million, or $0.02 per share of our common stock. Pro forma net tangible book value per share represents our net tangible book value divided by the number of shares of our common stock outstanding as of December 31, 2017, after giving effect to (i) the automatic conversion of all outstanding shares of our convertible preferred stock into 80,543,081 shares of our common stock, and (ii) the conversion of all outstanding warrants to purchase shares of our convertible preferred stock into warrants to purchase 423,784 shares of our common stock, in each case, immediately prior to the closing of this offering.

post

Insurance challenges have prevented Inspire from raising more money.

Now they're going public. Don't they still have coding issues?

post

Insurance challenges have prevented Inspire from raising more money.

I think Inspire presented at the JPM Morgan meeting. Good sign for them. I thought the company was dead.

post

Are they done? I know of a couple of reps who've been there and left.

I have written book and will tell you all about experience.


post

Insurance challenges have prevented Inspire from raising more money.

Are they done? I know of a couple of reps who've been there and left.

post

not sure what mdt's position is, but other suitors exist. JNJ is invested as well. The therapy works very well, the pt population (unwilling/unable to tolerate CPAP) is not insignificant, and the awareness of the consequences of unaddressed OSA continues to rise. Surpassing 1000 cases is impressive considering most have come after multi-level pre-d appeals, which means payers are losing the appeal battle which costs the payers money. If the competition comes out with good data, the payers won't be able to continue claiming investigational as a reason for denial.

Insurance challenges have prevented Inspire from raising more money.

post

not sure what mdt's position is, but other suitors exist. JNJ is invested as well. The therapy works very well, the pt population (unwilling/unable to tolerate CPAP) is not insignificant, and the awareness of the consequences of unaddressed OSA continues to rise. Surpassing 1000 cases is impressive considering most have come after multi-level pre-d appeals, which means payers are losing the appeal battle which costs the payers money. If the competition comes out with good data, the payers won't be able to continue claiming investigational as a reason for denial.

Who is the comp?

post

I've heard a number of reps have left over the years and Medtronic no longer interested in the company or re-investing.

not sure what mdt's position is, but other suitors exist. JNJ is invested as well. The therapy works very well, the pt population (unwilling/unable to tolerate CPAP) is not insignificant, and the awareness of the consequences of unaddressed OSA continues to rise. Surpassing 1000 cases is impressive considering most have come after multi-level pre-d appeals, which means payers are losing the appeal battle which costs the payers money. If the competition comes out with good data, the payers won't be able to continue claiming investigational as a reason for denial.

post

The only difference is now it is MRI compatible? Not enough change to make a difference for a product that has such a small patient market. Sorry.

Nice read

post

The only difference is now it is MRI compatible? Not enough change to make a difference for a product that has such a small patient market. Sorry.

I've heard a number of reps have left over the years and Medtronic no longer interested in the company or re-investing.

post

For ease of reading, we have uploaded the document linked in the previous post.

Medtech[y]

Inspire Medical Systems Announces FDA Approval of Inspire 3028 Neurostimulator for the Treatment of OSA by medtechy on Scribd

The only difference is now it is MRI compatible? Not enough change to make a difference for a product that has such a small patient market. Sorry.

post

Loading...


Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.